Pathophysiologic and treatment strategies for cardiovascular disease in end-stage renal disease and kidney transplantations

Cardiology in Review

Volumn 23, Issue 3, 2015, Pages 109-118

  Ghanta, Mythili ^a   Kozicky, Mark ^b   Jim, Belinda ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

cardiovascular disease; end stage renal disease; kidney transplantation; pathophysiology

Indexed keywords

ACEBUTOLOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BELATACEPT; CANDESARTAN; CARVEDILOL; CILAZAPRIL; CINACALCET; CORTICOSTEROID; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LABETALOL; LISINOPRIL; MINOXIDIL; NADOLOL; PARICALCITOL; RAMIPRIL; RAPAMYCIN; ROSUVASTATIN; VASODILATOR AGENT; VERAPAMIL; VITAMIN D DERIVATIVE;

ANEMIA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; END STAGE RENAL DISEASE; GRAFT RECIPIENT; HEART PROTECTION; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVING DONOR; METABOLIC SYNDROME X; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PREVENTIVE HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING CESSATION; SODIUM RESTRICTION; UREMIA; WATER DEPRIVATION; WEIGHT REDUCTION; CARDIOVASCULAR DISEASES; COMPLICATION; DISEASE MANAGEMENT; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY;

CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION;

EID: 84936891624     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000044     Document Type: Review

References (137)

1. Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002; 13: 745-753.
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-1305.
3. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005; 16: 489-495.
4. Collins AJ, Foley RN, Herzog C, et al. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis. 2010; 55: S1-420, A426-427.
5. Winkelmayer WC, Patrick AR, Liu J, et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol. 2011; 22: 349-357.
6. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci. 2003; 325: 163-167.
7. Vesely DL, Douglass MA, Dietz JR, et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation. 1994; 90: 1129-1140.
8. Lins RL, Elseviers M, Rogiers P, et al. Importance of volume factors in dialysis related hypertension. Clin Nephrol. 1997; 48: 29-33.
9. Glatter KA, Graves SW, Hollenberg NK, et al. Sustained volume expansion and [Na, K]ATPase inhibition in chronic renal failure. Am J Hypertens. 1994; 7: 1016-1025.
10. Chou KJ, Lee PT, Chen CL, et al. Physiological changes during hemodialysis in patients with intradialysis hypertension. Kidney Int. 2006; 69: 1833-1838.
11. Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001; 358: 2113-2117.
12. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis- stimulating agents (ESA). Clin J Am Soc Nephrol. 2009; 4: 470-480.
13. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999; 33: 821-828.
14. Mailloux LU. The overlooked role of salt restriction in dialysis patients. Semin Dial. 2000; 13: 150-151.
15. Flanigan MJ, Khairullah QT, Lim VS. Dialysate sodium delivery can alter chronic blood pressure management. Am J Kidney Dis. 1997; 29: 383-391.
16. Chazot C, Charra B, Laurent G, et al. Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant. 1995; 10: 831-837.
17. Chertow GM, Levin NW, Beck GJ, et al.; FHN Trial Group. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010; 363: 2287-2300.
18. Reisin E. Nonpharmacologic approaches to hypertension. Weight, sodium, alcohol, exercise, and tobacco considerations. Med Clin North Am. 1997; 81: 1289-1303.
19. Zazgornik J, Biesenbach G, Forstenlehner M, et al. Profile of antihypertensive drugs in hypertensive patients on renal replacement therapy (RRT). Clin Nephrol. 1997; 48: 337-340.
20. London GM, Marchais SJ, Guerin AP, et al. Salt and water retention and calcium blockade in uremia. Circulation. 1990; 82: 105-113.
21. Mailloux LU, Levey AS. Hypertension in patients with chronic renal disease. Am J Kidney Dis. 1998; 32(5 suppl 3): S120-S141.
22. Klingbeil AU, Schmieder RE. Not all left ventricular hypertrophy is created equal. Nephrol Dial Transplant. 1999; 14: 2803-2805.
23. Dyadyk AI, Bagriy AE, Lebed IA, et al. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant. 1997; 12: 945-951.
24. Verresen L, Waer M, Vanrenterghem Y, et al. Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet. 1990; 336: 1360-1362.
25. Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet. 1993; 24: 230-254.
26. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-The Losartan Heart Failure Survival Study ELITE II. Lancet. 2000; 355: 1582-1587.
27. Saracho R, Martin-Malo A, Martinez I, et al. Evaluation of the Losartan in Hemodialysis (ELHE) Study. Kidney Int Suppl. 1998; 68: S125-S129.
28. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334: 1349-1355.
29. Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet. 1996; 348: 1673-1674.
30. Ellsworth JL, Kraemer FB, Cooper AD. Transport of beta-very low density lipoproteins and chylomicron remnants by macrophages is mediated by the low density lipoprotein receptor pathway. J Biol Chem. 1987; 262: 2316-2325.
31. Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol. 1999; 19: 2474-2486.
32. Hodis HN. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation. 1999; 99: 2852-2854.
33. Ritz E, Wanner C. Lipid abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol. 2008; 19: 1065-1070.
34. Moradi H, Pahl MV, Elahimehr R, et al. Impaired antioxidant activity of highdensity lipoprotein in chronic kidney disease. Transl Res. 2009; 153: 77-85.
35. Lowrie EG, Lew NL. Commonly measured laboratory variables in hemodialysis patients: relationships among them and to death risk. Semin Nephrol. 1992; 12: 276-283.
36. Wanner C, Krane V, März W, et al.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-248.
37. Fellström BC, Jardine AG, Schmieder RE, et al.; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360: 1395-1407.
38. Drechsler C, Grootendorst DC, Pilz S, et al. Wasting and sudden cardiac death in hemodialysis patients: a post hoc analysis of 4D (Die Deutsche Diabetes Dialyse Studie). Am J Kidney Dis. 2011; 58: 599-607.
39. Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377: 2181-2192.
40. Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005; 16: 529-538.
41. Shoji T, Masakane I, Watanabe Y, et al.; Committee of Renal Data Registry, Japanese Society for Dialysis Therapy. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol. 2011; 6: 1112-1120.
42. Nakamura S, Ishibashi-Ueda H, Niizuma S, et al. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol. 2009; 4: 1892-1900.
43. Lindner A, Charra B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974; 290: 697-701.
44. Barreto FC, Barreto DV, Liabeuf S, et al.; European Uremic Toxin Work Group (EUTox). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009; 4: 1551-1558.
45. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol. 2007; 27: 30-35.
46. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol. 2011; 6: 30-39.
47. Chiu CA, Lu LF, Yu TH, et al. Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. Rev Diabet Stud. 2010; 7: 275-284.
48. Liabeuf S, Barreto DV, Barreto FC, et al.; European Uraemic Toxin Work Group (EUTox). Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant. 2010; 25: 1183-1191.
49. Meijers BK, Bammens B, De Moor B, et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int. 2008; 73: 1174-1180.
50. Bugnicourt JM, Da Silveira C, Bengrine A, et al. Chronic renal failure alters endothelial function in cerebral circulation in mice. Am J Physiol Heart Circ Physiol. 2011; 301: H1143-H1152.
51. Maduell F, Moreso F, Pons M, et al.; ESHOL Study Group. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013; 24: 487-497.
52. London GM, Guérin AP, Marchais SJ, et al. Arterial media calcification in endstage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18: 1731-1740.
53. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008; 19: 213-216.
54. . Lerner RG, Aronow WS, Sekhri A, et al. Warfarin use and the risk of valvular calcification. J Thromb Haemost. 2009; 7: 2023-2027.
55. Chen NX, Moe SM. Vascular calcification: pathophysiology and risk factors. Curr Hypertens Rep. 2012; 14: 228-237.
56. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.
57. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calciumbased phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007; 72: 1130-1137.
58. Walker MD, Silverberg SJ. Cardiovascular aspects of primary hyperparathyroidism. J Endocrinol Invest. 2008; 31: 925-931.
59. Walker MD, Fleischer J, Rundek T, et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab. 2009; 94: 3849-3856.
60. Saleh FN, Schirmer H, Sundsfjord J, et al. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J. 2003; 24: 2054-2060.
61. Rashid G, Bernheim J, Green J, et al. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol. 2007; 292: F1215-F1218.
62. Perkovic V, Hewitson TD, Kelynack KJ, et al. Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res. 2003; 26: 27-33.
63. Wu J, Garami M, Cheng T, et al. 1, 25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest. 1996; 97: 1577-1588.
64. Aladrén Regidor MJ. Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients. Clin Nephrol. 2009; 71: 207-213.
65. Lopez I, Mendoza FJ, Guerrero F, et al. The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. Am J Physiol Renal Physiol. 2009; 296: F1376-F1385.
66. Henley C, Colloton M, Cattley RC, et al. 1, 25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant. 2005; 20: 1370-1377.
67. Pritchett Y, Jemiai Y, Chang Y, et al. The use of group sequential, informationbased sample size re-estimation in the design of the PRIMO study of chronic kidney disease. Clin Trials. 2011; 8: 165-174.
68. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012; 307: 674-684.
69. Chertow GM, Block GA, Correa-Rotter R, et al.; EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012; 367: 2482-2494.
70. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int. 2004; 65: 626-633.
71. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590.
72. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int. 2012; 82: 235-241.
73. Drüeke TB, Locatelli F, Clyne N, et al.; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084.
74. Singh AK, Szczech L, Tang KL, et al.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098.
75. Pfeffer MA, Burdmann EA, Chen CY, et al.; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-2032.
76. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000; 356: 1213-1218.
77. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003; 107: 992-995.
78. Jun M, Venkataraman V, Razavian M, et al. Antioxidants for chronic kidney disease. Cochrane Database Syst Rev. 2012; 10: CD008176.
79. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341: 1725-1730.
80. Cai J, Terasaki PI. Induction immunosuppression improves long-Term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation. 2010; 90: 1511-1515.
81. Pilmore H, Dent H, Chang S, et al. Reduction in cardiovascular death after kidney transplantation. Transplantation. 2010; 89: 851-857.
82. West M, Sutherland DE, Matas AJ. Kidney transplant recipients who die with functioning grafts: serum creatinine level and cause of death. Transplantation. 1996; 62: 1029-1030.
83. Israni AK, Snyder JJ, Skeans MA, et al.; PORT Investigators. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant. 2010; 10: 338-353.
84. Israni AK, Snyder JJ, Skeans MA, et al.; PORT Investigators. Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant. Transpl Int. 2012; 25: 748-757.
85. Colvin-Adams M, Smith JM, Heubner BM, et al. OPTN/SRTR 2011 Annual Data Report: heart. Am J Transplant 2013; 13(suppl 1): 119-148.
86. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol. 2005; 16: 496-506.
87. Weiner DE, Carpenter MA, Levey AS, et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. Am J Transplant. 2012; 12: 2437-2445.
88. Silver SA, Huang M, Nash MM, et al. Framingham risk score and novel cardiovascular risk factors underpredict major adverse cardiac events in kidney transplant recipients. Transplantation. 2011; 92: 183-189.
89. Carpenter MA, Weir MR, Adey DB, et al. Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study. Clin Transplant. 2012; 26: E438-E446.
90. Lentine KL, Costa SP, Weir MR, et al.; American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Peripheral Vascular Disease. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2012; 60: 434-480.
91. Mohsin N, Mourad G, Faure M, et al. Metabolic syndrome performs better than the individual factors in predicting renal graft outcome. Transplant Proc. 2013; 45: 3517-3519.
92. Yadav AD, Chang YH, Aqel BA, et al. New onset diabetes mellitus in living donor versus deceased donor liver transplant recipients: analysis of the UNOS/OPTN database. J Transplant. 2013; 2013: 269096.
93. Ducloux D, Kazory A, Simula-Faivre D, et al. One-year post-Transplant weight gain is a risk factor for graft loss. Am J Transplant. 2005; 5: 2922-2928.
94. Cai J, Terasaki PI. The current trend of induction and maintenance treatment in patient of different PRA levels: a report on OPTN/UNOS Kidney Transplant Registry data. Clin Transpl. 2010: 45-52.
95. Chakkera HA, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation. 2013; 95: 647-652.
96. Woodle ES, First MR, Pirsch J, et al.; Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-Term, low-dose corticosteroid therapy. Ann Surg. 2008; 248: 564-577.
97. Ruangkanchanasetr P, Satirapoj B, Bunnag S, et al. High prevalence of obesity in Thai renal transplant recipients: a multicenter study. Transplant Proc. 2014; 46: 546-551.
98. Nakanome M, Sasaki H, Yazawa M, et al. Challenges for preventing the metabolic syndrome in kidney transplant recipients, initial report: survey of the current state of affairs before acting. Transplant Proc. 2014; 46: 543-545.
99. Chakkera HA, Weil EJ, Pham PT, et al. Can new-onset diabetes after kidney transplant be prevented?. Diabetes Care. 2013; 36: 1406-1412.
100. Mangray M, Vella JP. Hypertension after kidney transplant. Am J Kidney Dis. 2011; 57: 331-341.
101. Sander M, Lyson T, Thomas GD, et al. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens. 1996; 9: 121S-138S
102. Goodwin JE, Zhang J, Geller DS. A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension. J Am Soc Nephrol. 2008; 19: 1291-1299.
103. Aoyama H, Saigo K, Hasegawa M, et al. Pathologic findings of renal biopsy were a helpful diagnostic clue of stenosis of the iliac segment proximal to the transplant renal artery: a case report. Transplant Proc. 2014; 46: 651-653.
104. Aftab W, Varadarajan P, Rasool S, et al. Beta and angiotensin blockades are associated with improved 10-year survival in renal transplant recipients. J Am Heart Assoc. 2013; 2: e000091.
105. Opelz G, Döhler B. Cardiovascular death in kidney recipients treated with renin-Angiotensin system blockers. Transplantation. 2014; 97: 310-315.
106. Orlic L, Mikolasevic I, Sladoje-Martinovic B, et al. Use of angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in the early period after kidney transplantation. Coll Antropol. 2013; 37: 809-814.
107. Hillebrand U, Suwelack BM, Loley K, et al. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients. Transpl Int. 2009; 22: 1073-1080.
108. Cross NB, Webster AC, Masson P, et al. Antihypertensives for kidney transplant recipients: systematic review and meta-Analysis of randomized controlled trials. Transplantation. 2009; 88: 7-18.
109. Kiberd BA. Post-Transplant erythrocytosis: a disappearing phenomenon?. Clin Transplant. 2009; 23: 800-806.
110. Soypacaci Z, Sengul S, Yildiz EA, et al. Effect of daily sodium intake on post-Transplant hypertension in kidney allograft recipients. Transplant Proc. 2013; 45: 940-943.
111. Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant. 2012; 12: 1975-1982.
112. De Giorgi A, Fabbian F. Immunosuppression in renal transplantation and dyslipidemia, which factors should be considered?. Nephrourol Mon. 2013; 5: 1008-1009.
113. Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism. 2011; 60: 1500-1510.
114. Jiang Y, Xie XB, Peng LK, et al. Dyslipidemia in human kidney transplant recipients receiving cyclosporine and tacrolimus is associated with different expression of CD36 on peripheral blood monocytes. Transplant Proc. 2011; 43: 1612-1615.
115. Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant. 2008; 8: 1384-1392.
116. Claes K, Meier-Kriesche HU, Schold JD, et al. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant. 2012; 27: 850-857.
117. Spinelli GA, Felipe CR, Park SI, et al. Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen. Transplant Proc. 2011; 43: 3730-3737.
118. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2014; 1: CD005019.
119. Scarfia RV, Clementi A, Granata A. Rhabdomyolysis and acute kidney injury secondary to interaction between simvastatin and cyclosporine. Ren Fail. 2013; 35: 1056-1057.
120. Wanner C, Krämer-Guth A, Galle J. Use of HMG-CoA reductase inhibitors after kidney and heart transplantation: lipid-lowering and immunosuppressive effects. BioDrugs. 1997; 8: 387-393.
121. Cohen JB, Gordon CE, Balk EM, et al. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-Analysis. Transplantation. 2012; 94: 1041-1048.
122. Paschoalin RP, Torregrosa JV, Sánchez-Escuredo A, et al. Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-Term follow-up. Transplant Proc. 2012; 44: 2588-2589.
123. Lee MC, Chen YC, Ho GJ, et al. Serum leptin levels positively correlate with peripheral arterial stiffness in kidney transplantation patients. Transplant Proc. 2014; 46: 353-358.
124. Schankel K, Robinson J, Bloom RD, et al. Determinants of coronary artery calcification progression in renal transplant recipients. Am J Transplant. 2007; 7: 2158-2164.
125. Yuen D, Pierratos A, Richardson RM, et al. The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients. Nephrol Dial Transplant. 2006; 21: 1407-1412.
126. Vanrenterghem YF, Claes K, Montagnino G, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation. 2008; 85: 209-216.
127. Sinkeler SJ, Zelle DM, Homan van der Heide JJ, et al. Endogenous plasma erythropoietin, cardiovascular mortality and all-cause mortality in renal transplant recipients. Am J Transplant. 2012; 12: 485-491.
128. Bansal N, Tighiouart H, Weiner D, et al. Anemia as a risk factor for kidney function decline in individuals with heart failure. Am J Cardiol. 2007; 99: 1137-1142.
129. Yoo SW, Kwon OJ, Kang CM. Preemptive living-donor renal transplantation: outcome and clinical advantages. Transplant Proc. 2009; 41: 117-120.
130. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant 2014; 14(suppl 1): 11-44.
131. Molnar MZ, Streja E, Kovesdy CP, et al. Age and the associations of living donor and expanded criteria donor kidneys with kidney transplant outcomes. Am J Kidney Dis. 2012; 59: 841-848.
132. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation. 2006; 81: 643-654.
133. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011; 91: 976-983.
134. Charpentier B, Medina Pestana JO, Del C Rial M, et al. Long-Term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant. 2013; 13: 2884-2891.
135. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010; 10: 535-546.
136. Chadban SJ, Eris JM, Kanellis J, et al.; SOCRATES Study Group. A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Transpl Int. 2014; 27: 302-311.
137. Ponticelli C. The pros and the cons of mTOR inhibitors in kidney transplantation. Expert Rev Clin Immunol. 2014; 10: 295-305.